Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

MEBO Metabolic Malodor Survey (international) for Dr Hazen click here
click to Read more/less

survey for ANYONE who identifies with METABOLIC MALODOR

begun : Oct20
end : no ending for now

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

This is a GOOGLE FORMS survey

short url for survey :

current participants : 113 (update 18dec20)

Saturday, January 31, 2009

Some extracts on FMO enzymes in books via googlebooks

The Flavin Mono-oxygenase 3 enzyme is said to be flawed in a diagnosis of Primary Trimethylaminuria (despite anecdotal test results of DNA suggesting otherwise, and also a dissertation where 8/12 had no mutants/variants). The enzyme deals with a lot of odorous substrates; sulfides and amines and phosphorus compounds. As textbooks currently say, since these other compounds are thought to be able to go a slower complex alternative route, via the P450 enzymes, (P450 and FMO are regarded as a layer of oxidizing activating/detoxing enzymes - the phase 1 enzymes) the other sulfides and amines aren't regarded as un-oxidizable as trimethylamine is. Perhaps this enzyme will turn out to be the main 'smelly' enzyme and perhaps the problem is to do with a backlog of these substrates. Trimethylamine doesn't seem to explain fecal body odor, whereas other sulfides and amines seem plausible.

For this reason, it is probabably useful to know about these enzymes, and in particular, FMO3. This is a good extract from a 2003 Molecular Toxicology book about the FMO family of enzymes.

Molecular Toxicology By Nick Plant: FMO

This chapter is from a 'gold standard' 2001 medical book on toxicology, the chapter dealing with the xenobiotic metabolizing enzymes (aka drug metabolizing enzymes, first pass enzymes, phase1/phase2 enzymes).

Casarett and Doull's Toxicology: Biotransformation of xenobiotics


Post a Comment